Cargando…
Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit?
PURPOSE: The aim of the present study was to evaluate the effectiveness of hyaluronic acid (HA) in the prevention of acute and late vaginal toxicities after high-dose-rate (HDR) vaginal brachytherapy (BT). MATERIAL AND METHODS: Between January 2011 and January 2015, we retrospectively analyzed 126 p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241378/ https://www.ncbi.nlm.nih.gov/pubmed/28115957 http://dx.doi.org/10.5114/jcb.2016.64511 |
_version_ | 1782496176911679488 |
---|---|
author | Laliscia, Concetta Delishaj, Durim Fabrini, Maria Grazia Gonnelli, Alessandra Morganti, Riccardo Perrone, Franco Tana, Roberta Paiar, Fabiola Gadducci, Angiolo |
author_facet | Laliscia, Concetta Delishaj, Durim Fabrini, Maria Grazia Gonnelli, Alessandra Morganti, Riccardo Perrone, Franco Tana, Roberta Paiar, Fabiola Gadducci, Angiolo |
author_sort | Laliscia, Concetta |
collection | PubMed |
description | PURPOSE: The aim of the present study was to evaluate the effectiveness of hyaluronic acid (HA) in the prevention of acute and late vaginal toxicities after high-dose-rate (HDR) vaginal brachytherapy (BT). MATERIAL AND METHODS: Between January 2011 and January 2015, we retrospectively analyzed 126 patients with endometrial cancer who underwent extrafascial hysterectomy with or without lymphadenectomy and adjuvant HDR-vaginal BT +/– adjuvant chemotherapy. The total dose prescription was 21 Gy in 3 fractions (one fraction for week). Vaginal ovules containing 5 mg of HA were given for whole duration of vaginal BT and for the two following weeks. Acute and late toxicities were evaluated according to CTCAE vs 4.02. RESULTS: According to the revised FIGO 2009 classification, most tumors were in stage IA (30.9%) and in stage IB (57.9%). Thirty-three patients (26.2%) received adjuvant chemotherapy before vaginal BT. Five-year disease-free survival (DFS) and five-year overall survival (OS) were 88% and 93%, respectively. The most common grade 1-2 acute toxicities were vaginal inflammation (18 patients, 14.3%) and dyspareunia (7 patients, 5.5%). Two patients (1.6%) had more than one toxicity. Late toxicity occurred in 20 patients (15.9%). Grade 1-2 late toxicities were fibrosis (14 patients, 11.1%) and telangiectasias (7 patients, 5.5%). Six patients (4.8%) had more than one late toxicity. No grade 3 or higher acute or late toxicities were observed. CONCLUSIONS: These results appear to suggest that the local therapy with HA is of clinical benefit for intermediate risk endometrial cancer patients who receive adjuvant HDR-vaginal BT after surgery. A randomized trial comparing HA treatment vs. no local treatment in this clinical setting is warranted to further evaluate the efficacy of HA in preventing vaginal BT-related vaginal toxicity. |
format | Online Article Text |
id | pubmed-5241378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-52413782017-01-23 Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit? Laliscia, Concetta Delishaj, Durim Fabrini, Maria Grazia Gonnelli, Alessandra Morganti, Riccardo Perrone, Franco Tana, Roberta Paiar, Fabiola Gadducci, Angiolo J Contemp Brachytherapy Original Paper PURPOSE: The aim of the present study was to evaluate the effectiveness of hyaluronic acid (HA) in the prevention of acute and late vaginal toxicities after high-dose-rate (HDR) vaginal brachytherapy (BT). MATERIAL AND METHODS: Between January 2011 and January 2015, we retrospectively analyzed 126 patients with endometrial cancer who underwent extrafascial hysterectomy with or without lymphadenectomy and adjuvant HDR-vaginal BT +/– adjuvant chemotherapy. The total dose prescription was 21 Gy in 3 fractions (one fraction for week). Vaginal ovules containing 5 mg of HA were given for whole duration of vaginal BT and for the two following weeks. Acute and late toxicities were evaluated according to CTCAE vs 4.02. RESULTS: According to the revised FIGO 2009 classification, most tumors were in stage IA (30.9%) and in stage IB (57.9%). Thirty-three patients (26.2%) received adjuvant chemotherapy before vaginal BT. Five-year disease-free survival (DFS) and five-year overall survival (OS) were 88% and 93%, respectively. The most common grade 1-2 acute toxicities were vaginal inflammation (18 patients, 14.3%) and dyspareunia (7 patients, 5.5%). Two patients (1.6%) had more than one toxicity. Late toxicity occurred in 20 patients (15.9%). Grade 1-2 late toxicities were fibrosis (14 patients, 11.1%) and telangiectasias (7 patients, 5.5%). Six patients (4.8%) had more than one late toxicity. No grade 3 or higher acute or late toxicities were observed. CONCLUSIONS: These results appear to suggest that the local therapy with HA is of clinical benefit for intermediate risk endometrial cancer patients who receive adjuvant HDR-vaginal BT after surgery. A randomized trial comparing HA treatment vs. no local treatment in this clinical setting is warranted to further evaluate the efficacy of HA in preventing vaginal BT-related vaginal toxicity. Termedia Publishing House 2016-12-09 2016-12 /pmc/articles/PMC5241378/ /pubmed/28115957 http://dx.doi.org/10.5114/jcb.2016.64511 Text en Copyright: © 2016 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Laliscia, Concetta Delishaj, Durim Fabrini, Maria Grazia Gonnelli, Alessandra Morganti, Riccardo Perrone, Franco Tana, Roberta Paiar, Fabiola Gadducci, Angiolo Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit? |
title | Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit? |
title_full | Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit? |
title_fullStr | Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit? |
title_full_unstemmed | Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit? |
title_short | Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit? |
title_sort | acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit? |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241378/ https://www.ncbi.nlm.nih.gov/pubmed/28115957 http://dx.doi.org/10.5114/jcb.2016.64511 |
work_keys_str_mv | AT lalisciaconcetta acuteandlatevaginaltoxicityafteradjuvanthighdoseratevaginalbrachytherapyinpatientswithintermediateriskendometrialcancerislocaltherapywithhyaluronicacidofclinicalbenefit AT delishajdurim acuteandlatevaginaltoxicityafteradjuvanthighdoseratevaginalbrachytherapyinpatientswithintermediateriskendometrialcancerislocaltherapywithhyaluronicacidofclinicalbenefit AT fabrinimariagrazia acuteandlatevaginaltoxicityafteradjuvanthighdoseratevaginalbrachytherapyinpatientswithintermediateriskendometrialcancerislocaltherapywithhyaluronicacidofclinicalbenefit AT gonnellialessandra acuteandlatevaginaltoxicityafteradjuvanthighdoseratevaginalbrachytherapyinpatientswithintermediateriskendometrialcancerislocaltherapywithhyaluronicacidofclinicalbenefit AT morgantiriccardo acuteandlatevaginaltoxicityafteradjuvanthighdoseratevaginalbrachytherapyinpatientswithintermediateriskendometrialcancerislocaltherapywithhyaluronicacidofclinicalbenefit AT perronefranco acuteandlatevaginaltoxicityafteradjuvanthighdoseratevaginalbrachytherapyinpatientswithintermediateriskendometrialcancerislocaltherapywithhyaluronicacidofclinicalbenefit AT tanaroberta acuteandlatevaginaltoxicityafteradjuvanthighdoseratevaginalbrachytherapyinpatientswithintermediateriskendometrialcancerislocaltherapywithhyaluronicacidofclinicalbenefit AT paiarfabiola acuteandlatevaginaltoxicityafteradjuvanthighdoseratevaginalbrachytherapyinpatientswithintermediateriskendometrialcancerislocaltherapywithhyaluronicacidofclinicalbenefit AT gadducciangiolo acuteandlatevaginaltoxicityafteradjuvanthighdoseratevaginalbrachytherapyinpatientswithintermediateriskendometrialcancerislocaltherapywithhyaluronicacidofclinicalbenefit |